Please login to the form below

Not currently logged in
Email:
Password:

blood diseases

This page shows the latest blood diseases news and features for those working in and with pharma, biotech and healthcare.

Novo Nordisk’s collaboration with MIT and BWH expanded

Novo Nordisk’s collaboration with MIT and BWH expanded

Novo Nordisk, founded in 1923 and headquartered in Denmark, is a leading global healthcare company working to drive change to defeat diabetes and other serious chronic diseases such as obesity and ... rare blood and endocrine disorders by pioneering

Latest news

More from news
Approximately 1 fully matching, plus 22 partially matching documents found.

Latest Intelligence

  • ASH 2022: bad blood but big advances ASH 2022: bad blood but big advances

    The message? Bad Blood isn’t just a Taylor Swift anthem, it’s the root cause of life-limiting diseases – liquid cancers and non-malignant blood disorders – that haven’t traditionally ... That’s understandable; the prevalence of major cancers

  • 20 for 2020 – Five pharma leaders to watch in 2020 20 for 2020 – Five pharma leaders to watch in 2020

    In the meantime, Sanofi is stepping up its focus in other areas like immunological and inflammatory diseases, rare blood disorders and vaccines, as well as cancer – an area it had been ... Meanwhile, Galapagos looks set to continue adding to its

  • Delivering the promise of regenerative medicine Delivering the promise of regenerative medicine

    Our own cells will also be able to treat and cure diseases and conditions of the blood and immune system, as well as restore the blood system after treatments for specific ... Regenerative medicine is poised to transform healthcare as we know it,

  • Bluebird Bio: on the cusp of a gene therapy revolution Bluebird Bio: on the cusp of a gene therapy revolution

    The US biotech company aims to have four groundbreaking gene therapies launched by 2022 – with the promise of lives transformed in each of these rare blood diseases – and realistic hope of ... Interim trial data showed the therapy can reduce by 30-60%

  • Deal Watch January 2018

    Sanofi was also interested in caplacizumab, which fits not only with its rare disease focus but also enhances its portfolio of products for rare blood diseases coming from its acquisition of ... The company has a focus in neurodegenerative diseases and a

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

  • Gamida Cell strengthens leadership team Gamida Cell strengthens leadership team

    Their combined experience in corporate strategy, business development and commercialisation will be invaluable to the company’s continued growth as we advance our clinical programmes in blood cancers and rare genetic ... diseases.”.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Graphite Digital

We’re a digital CX agency collaborating with healthcare and pharmaceutical organisations to help them connect more deeply with their audiences...

Latest intelligence

World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
Great Expectations – exploring the counterpoint between advances in oncology and the challenges of ensuring life-changing medicines reach patients...
Strategic behaviour
Strong strategising depends on your colleagues’ behaviour...
Pharmaceutical Marketing Strategies For The Digital Age
In the digital age, a strong digital marketing strategy is crucial for businesses, especially in the highly competitive and complex pharmaceutical industry. There are key trends shaping pharmaceutical marketing, such...